Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

BLKB October 14, 2025

Blackbaud Second Quarter 2025 Earnings Call - Raised Guidance After Strong Q2; AI Monetization and Cash Flow Optionality in Focus

Blackbaud reported a robust Q2 with revenue of $281.0 million, 6.8% organic growth, adjusted EBITDA margin of 38.5% and non GAAP EPS of $1.21, driven by transaction strength and continued margin expan...

  • Q2 revenue $281.0 million, organic growth 6.8% year over year.
  • Adjusted EBITDA margin 38.5%, up nearly 300 basis points year over year.
  • Non GAAP diluted EPS $1.21, up 12% year over year, with outperformance if adjusted for EverFi.
  • +16 more takeaways
AVTR October 14, 2025

Avantor Q2 2025 Earnings Call - Bioprocessing setbacks and price-led share gains squeeze margins

Avantor delivered a mixed quarter. Reported revenue was $1.68 billion, organic revenue flat year over year, but margins slipped as management chose price and mix to protect and win accounts. Adjusted ...

  • Reported revenue $1.68 billion in Q2 2025, organic revenue flat year over year.
  • Adjusted gross profit $554 million, adjusted gross margin 32.9%, down 130 basis points year over year driven mainly by price actions, unfavorable mix, higher freight and fixed cost under absorption.
  • Adjusted EBITDA $280 million, 16.6% margin, down roughly 125 basis points year over year; adjusted operating income $252 million, 15% margin.
  • +11 more takeaways
EMN October 14, 2025

Eastman Chemical Company Second Quarter 2025 Earnings Call - Trade Uncertainty Pulls Inventory, Hits H2 Utilization; Methanolysis Debottlenecking Offers Durable Upside

Eastman spent most of this call describing a simple, ugly narrative. A sudden escalation in global tariffs has injected chaos into supply chains, triggered pre-buys in Q2 and then order holds in July,...

  • Tariffs and trade policy are the dominant story, creating chaotic supply-chain behavior and distorting Q2 to H2 demand signals across Eastman’s portfolio.
  • Management expects a mid single digit decline in demand into the back half of 2025, driven by pre-buys in Q2, customers holding orders in July, and normal seasonality.
  • Inventory reduction to free cash is a deliberate strategy, and that action creates an accounting-related utilization headwind of about $75 million to $100 million in H2 2025.
  • +12 more takeaways
VIRT October 14, 2025

Virtu Financial Q2 2025 Earnings Call - Record $568M Trading Quarter Fueled by Volatility, Crypto and ETF Block Strength

Virtu delivered a blowout Q2 2025, posting $568 million in adjusted net trading income, a record $9.2 million per day, and normalized adjusted EPS of $1.53, up sharply year over year. The surge was dr...

  • Adjusted net trading income hit $568 million in Q2 2025, a record and equal to $9.2 million per trading day, up 50% from $6.1 million per day in Q2 2024.
  • Normalized adjusted EPS was $1.53 for the quarter, an 83% increase year over year.
  • Adjusted EBITDA margin was 65%, the highest since the referenced prior peak, driven by disciplined expense management and $198 million in adjusted cash operating expenses.
  • +12 more takeaways
SITE October 14, 2025

SiteOne Landscape Supply Q2 2025 Earnings Call - Resilient execution drives EBITDA margin expansion despite flat organic sales

SiteOne reported a quarter of disciplined fixes and cautious progress. Net sales rose 3% helped by acquisitions, while organic daily sales were flat. Management delivered the kind of operational wins ...

  • Net sales +3% in Q2 2025, driven by 3% from acquisitions and flat organic daily sales versus prior year.
  • Adjusted EBITDA increased 8% to $226.7 million; adjusted EBITDA margin improved 60 basis points to 15.5%.
  • Organic daily sales were flat, reflecting soft end markets offset by continued market share gains.
  • +12 more takeaways
REYN October 14, 2025

Reynolds Consumer Products Q2 2025 Earnings Call - Pricing, Innovation and Onshoring to Offset Cost Pressures

Reynolds reported a steady quarter, essentially in line with guidance, with net revenues of $938 million and retail revenue flat at $887 million. Adjusted EPS was $0.39, slightly below last year when ...

  • Net revenues for Q2 were $938 million, up from $930 million a year ago, with retail revenue flat at $887 million.
  • Adjusted EPS was $0.39 in Q2 2025, versus $0.41 in the year ago period after adjusting for a discrete tax benefit.
  • Management attributes the Q2 gross profit decline to timing mismatches, not structural margin loss, and expects pricing to catch up through the year.
  • +13 more takeaways
EDU October 14, 2025

New Oriental FY2025 Fourth Quarter Earnings Call - Board Commits at Least 50% of Net Income to Shareholders after $700M Buyback

New Oriental closed FY2025 with better-than-expected Q4 operating momentum, driven by new ventures, tourism and improved operating leverage, but management is dialing back near-term revenue expectatio...

  • Q4 total net revenue excluding Easter buy private label and live streaming rose 18.7% year over year, management says, with new ventures cited as the main contributor.
  • Non-GAAP operating margin excluding Easter buy reached 6.5% in Q4, a year over year improvement of about 410 basis points, credited to operating leverage and cost controls initiated since March.
  • GAAP operating loss was $8.7 million in the quarter versus operating income of $10.5 million a year ago; non-GAAP operating income (ex-SBC, amortization and the kindergarten goodwill impairment) was $81.7 million, up 116.3% year over year.
  • +12 more takeaways
LXP October 14, 2025

LXP Industrial Trust Q2 2025 Earnings Call - Lease-up of 1,100,000 sq ft Greenville-Spartanburg development and leverage progress

LXP reported a quietly solid quarter, driven by the lease up of a 1.1 million square foot development in Greenville Spartanburg, steady same-store NOI growth, and deliberate deleveraging. Management t...

  • Leased a 1,100,000 square foot development in Greenville Spartanburg to a U.S. subsidiary of a global logistics company, immediate occupancy, low TI, annual cash base rent roughly $6.0 million, cash rent commences August 1.
  • Adjusted company FFO for Q2 was $0.16 per diluted common share, approximately $47.0 million, and 2025 adjusted company FFO guidance tightened to $0.62 to $0.64.
  • Same-store NOI grew 4.7% in Q2, same-store portfolio was 98% leased at quarter end, and full-year same-store NOI growth guidance remains 3% to 4% assuming year-end same-store occupancy of 97% to 99%.
  • +11 more takeaways
SXI October 14, 2025

Standex International Fiscal Fourth Quarter 2025 Earnings Call - Company says FY2026 is an inflection year, targeting >$100M revenue lift driven by acquisitions, new products and fast-growth markets

Standex delivered a quarter that looks more like a strategic turning point than a routine report. Q4 revenue rose 23.2% to $222 million, driven almost entirely by acquisitions (23.4%), while organic r...

  • Q4 revenue up 23.2% year over year to $222 million, but organic revenue fell 1.4%, with acquisitions contributing ~23.4% of the increase.
  • Adjusted operating margin reached a record 20.6% in Q4, up 350 basis points year over year; management calls this the third consecutive quarter of record profit generation.
  • Management expects fiscal 2026 to deliver more than $100 million of incremental revenue, driven by acquisitions, new products, and fast-growth end markets.
  • +13 more takeaways
OPCH October 14, 2025

Option Care Health Q2 2025 Earnings Call - Raised 2025 Guidance After 15% Revenue Gain and Strong Cash Generation

Option Care Health posted a strong Q2, with revenue up 15.4% year over year and balanced mid teens growth across both acute and chronic portfolios. Management raised full year 2025 guidance, citing re...

  • Revenue grew 15.4% year over year in Q2 2025, with mid teens expansion in both acute and chronic therapy portfolios.
  • Management raised full year 2025 guidance to revenue of $5.50 billion to $5.65 billion, adjusted EBITDA $465 million to $475 million, and adjusted EPS $1.65 to $1.72.
  • Gross profit was $269 million, up about 8% year over year, though gross margin rate was pressured by mix from limited distribution and rare and orphan therapies.
  • +12 more takeaways